Skip to main content

DarioHealth Corp.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

DRIO$2.39+16.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENT OF CASH FLOWS

​​​​​​​
​ · ​ · Year ended
​ · ​ · December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024
Cash flows from operating activities:​​​​​​
Net loss​$(41,714)​$(42,747)
Adjustments required to reconcile net loss to net cash used in operating activities:​​​​
Stock-based compensation​9,365​15,796
Change in operating lease right of use assets​421​907
Amortization of acquired intangible assets​2,831​6,100
Depreciation and impairment​​307​​1,327
Change in fair value of warrant liability​(1,681)​(16,504)
Accrued interest on short term bank deposits​​(14)​​—
Non-cash financial expenses​2,933​516
Changes in operating assets and liabilities, net of effects of businesses acquired:​​​​​​
Decrease in trade receivables, net​2,660​1,680
Increase in other accounts receivable, prepaid expense and long-term assets​(16)​(80)
Decrease in inventories​437​308
Decrease in trade payables​(122)​(496)
Decrease in other accounts payable and accrued expenses​(780)​(3,483)
Decrease in deferred revenues​(869)​(156)
Change in operating lease liabilities​(341)​(1,150)
Other​642​(580)
​​​​​​​
Net cash used in operating activities​(25,941)​(38,562)
​​​​​​​
Cash flows from investing activities:​​​​
Purchase of property and equipment, net​(142)​(138)
Investments in short-term bank deposits​​(4,200)​​—
Payments for business acquisitions, net of cash acquired​​—​​(8,796)
​​​​​​​
Net cash used in investing activities​(4,342)​(8,934)
​​​​​​​
Cash flows from financing activities:​​​​
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs​​17,374​​—
Proceeds from issuance of preferred stock, net of issuance costs​6,754​38,531
Proceeds from borrowings on credit agreement, Net of issuance cost​​31,700​​—
Repayment of long-term loan​​(31,515)​​—
​​​​​​​
Net cash provided by financing activities​24,313​38,531
​​​​​​​
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents​(5,970)​(8,965)
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents​​9​​(68)
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period​27,764​36,797
Cash, cash equivalents and restricted cash and cash equivalents at end of period​$21,803​$27,764
Supplemental disclosure of cash flow information:​​​​
Cash paid during the period for interest on long-term loan​$3,493​$3,927
Non-cash activities:​​​​
Right-of-use assets obtained in exchange for lease liabilities​$73​$428
Purchase of property and equipment on credit​​5​​—
Exercise of pre-funded warrants to common stock upon acquisition​$2,821​$2,225
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.